Recent studies have also shown that BRCA-deficient tumors have elevated expression levels of programmed cell death protein 1 (PD-1) and programmed cell death ligand 1 (PD-L1) in tumor-associated immune cells, indicating that checkpoint inhibitors may be useful in the treatment of BRCA-associated cancers (89–91). This evidence concerns the gene CD274 and neoplasm.